Association Between Time to Operation and Pathologic Stage in Ductal Carcinoma in Situ and Early-Stage Hormone Receptor-Positive Breast Cancer.
Identifieur interne : 000735 ( Main/Curation ); précédent : 000734; suivant : 000736Association Between Time to Operation and Pathologic Stage in Ductal Carcinoma in Situ and Early-Stage Hormone Receptor-Positive Breast Cancer.
Auteurs : Christina A. Minami [États-Unis] ; Olga Kantor [États-Unis] ; Anna Weiss [États-Unis] ; Faina Nakhlis [États-Unis] ; Tari A. King [États-Unis] ; Elizabeth A. Mittendorf [États-Unis]Source :
- Journal of the American College of Surgeons [ 1879-1190 ] ; 2020.
Descripteurs français
- KwdFr :
- Adolescent (MeSH), Adulte (MeSH), Adulte d'âge moyen (MeSH), Betacoronavirus (MeSH), Carcinome canalaire du sein (chirurgie), Carcinome canalaire du sein (diagnostic), Carcinome canalaire du sein (épidémiologie), Comorbidité (MeSH), Délai jusqu'au traitement (MeSH), Facteurs de risque (MeSH), Facteurs temps (MeSH), Femelle (MeSH), Humains (MeSH), Infections à coronavirus (épidémiologie), Jeune adulte (MeSH), Marqueurs biologiques tumoraux (métabolisme), Mastectomie (méthodes), Pandémies (MeSH), Pneumopathie virale (épidémiologie), Pronostic (MeSH), Récepteurs des oestrogènes (métabolisme), Stadification tumorale (MeSH), Sujet âgé (MeSH), Sujet âgé de 80 ans ou plus (MeSH), Taux de survie (tendances), Tumeurs du sein (chirurgie), Tumeurs du sein (diagnostic), Tumeurs du sein (épidémiologie), États-Unis (épidémiologie), Études de suivi (MeSH), Études rétrospectives (MeSH).
- MESH :
- chirurgie : Carcinome canalaire du sein, Tumeurs du sein.
- diagnostic : Carcinome canalaire du sein, Tumeurs du sein.
- métabolisme : Marqueurs biologiques tumoraux, Récepteurs des oestrogènes.
- méthodes : Mastectomie.
- tendances : Taux de survie.
- épidémiologie : Carcinome canalaire du sein, Infections à coronavirus, Pneumopathie virale, Tumeurs du sein, États-Unis.
- Adolescent, Adulte, Adulte d'âge moyen, Betacoronavirus, Comorbidité, Délai jusqu'au traitement, Facteurs de risque, Facteurs temps, Femelle, Humains, Jeune adulte, Pandémies, Pronostic, Stadification tumorale, Sujet âgé, Sujet âgé de 80 ans ou plus, Études de suivi, Études rétrospectives.
- Wicri :
- geographic : États-Unis.
English descriptors
- KwdEn :
- Adolescent (MeSH), Adult (MeSH), Aged (MeSH), Aged, 80 and over (MeSH), Betacoronavirus (MeSH), Biomarkers, Tumor (metabolism), Breast Neoplasms (diagnosis), Breast Neoplasms (epidemiology), Breast Neoplasms (surgery), Carcinoma, Ductal, Breast (diagnosis), Carcinoma, Ductal, Breast (epidemiology), Carcinoma, Ductal, Breast (surgery), Comorbidity (MeSH), Coronavirus Infections (epidemiology), Female (MeSH), Follow-Up Studies (MeSH), Humans (MeSH), Mastectomy (methods), Middle Aged (MeSH), Neoplasm Staging (MeSH), Pandemics (MeSH), Pneumonia, Viral (epidemiology), Prognosis (MeSH), Receptors, Estrogen (metabolism), Retrospective Studies (MeSH), Risk Factors (MeSH), Survival Rate (trends), Time Factors (MeSH), Time-to-Treatment (MeSH), United States (epidemiology), Young Adult (MeSH).
- MESH :
- chemical , metabolism : Biomarkers, Tumor, Receptors, Estrogen.
- geographic , epidemiology : United States.
- diagnosis : Breast Neoplasms, Carcinoma, Ductal, Breast.
- epidemiology : Breast Neoplasms, Carcinoma, Ductal, Breast, Coronavirus Infections, Pneumonia, Viral.
- methods : Mastectomy.
- surgery : Breast Neoplasms, Carcinoma, Ductal, Breast.
- trends : Survival Rate.
- Adolescent, Adult, Aged, Aged, 80 and over, Betacoronavirus, Comorbidity, Female, Follow-Up Studies, Humans, Middle Aged, Neoplasm Staging, Pandemics, Prognosis, Retrospective Studies, Risk Factors, Time Factors, Time-to-Treatment, Young Adult.
Abstract
BACKGROUND
During the COVID-19 pandemic, surgical delays have been common for patients with ductal carcinoma in situ (DCIS) and early-stage estrogen receptor-positive (ER+) breast cancer, often in favor of neoadjuvant endocrine therapy (NET). To understand possible ramifications of these delays, we examined the association between time to operation and pathologic staging and overall survival (OS).
STUDY DESIGN
Patients with DCIS or ER+ cT1-2N0 breast cancer treated from 2010 through 2016 were identified in the National Cancer Database. Time to operation was recorded. Factors associated with pathologic upstaging were examined using logistic regression analyses. Cox proportional hazard models were used to analyze OS. Analyses were stratified by disease stage and initial treatment strategy.
RESULTS
There were 378,839 patients identified. Among those undergoing primary surgical procedure, time to operation was within 120 days in > 98% in all groups. Among cT1-2N0 patients selected for NET, operations were performed within 120 days in 59.6% of cT1N0 and 30.9% of cT2N0 patients. Increased time to operation was associated with increased odds of pathologic upstaging in DCIS patients (ER+: 60 to 120 days: odds ratio 1.15; 95% CI, 1.08 to 1.22; more than 120 days: odds ratio 1.44; 95% CI, 1.24 to 1.68; ER-: 60 to 120 days: NS; more than 120 days: odds ratio 1.36; 95% CI, 1.01 to 1.82; 60 days or less: reference), but not in patients with invasive cancer, irrespective of initial treatment strategy. No difference in OS was seen by time to operation in DCIS or NET patients.
CONCLUSIONS
Increased time to operation was associated with a small increase in pathologic upstaging in DCIS patients, but did not impact OS. In patients with cT1-2N0 disease, NET use did not impact stage or OS, supporting the safety of delay strategies in ER+ breast cancer patients during the pandemic.
DOI: 10.1016/j.jamcollsurg.2020.06.021
PubMed: 32771654
PubMed Central: PMC7409804
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000735
Links to Exploration step
pubmed:32771654Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Association Between Time to Operation and Pathologic Stage in Ductal Carcinoma in Situ and Early-Stage Hormone Receptor-Positive Breast Cancer.</title>
<author><name sortKey="Minami, Christina A" sort="Minami, Christina A" uniqKey="Minami C" first="Christina A" last="Minami">Christina A. Minami</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, and Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, and Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Kantor, Olga" sort="Kantor, Olga" uniqKey="Kantor O" first="Olga" last="Kantor">Olga Kantor</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, and Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, and Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Weiss, Anna" sort="Weiss, Anna" uniqKey="Weiss A" first="Anna" last="Weiss">Anna Weiss</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, and Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, and Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Nakhlis, Faina" sort="Nakhlis, Faina" uniqKey="Nakhlis F" first="Faina" last="Nakhlis">Faina Nakhlis</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, and Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, and Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="King, Tari A" sort="King, Tari A" uniqKey="King T" first="Tari A" last="King">Tari A. King</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, and Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, and Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Mittendorf, Elizabeth A" sort="Mittendorf, Elizabeth A" uniqKey="Mittendorf E" first="Elizabeth A" last="Mittendorf">Elizabeth A. Mittendorf</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, and Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA. Electronic address: emittendorf@bwh.harvard.edu.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, and Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston</wicri:cityArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32771654</idno>
<idno type="pmid">32771654</idno>
<idno type="doi">10.1016/j.jamcollsurg.2020.06.021</idno>
<idno type="pmc">PMC7409804</idno>
<idno type="wicri:Area/Main/Corpus">000735</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000735</idno>
<idno type="wicri:Area/Main/Curation">000735</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000735</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Association Between Time to Operation and Pathologic Stage in Ductal Carcinoma in Situ and Early-Stage Hormone Receptor-Positive Breast Cancer.</title>
<author><name sortKey="Minami, Christina A" sort="Minami, Christina A" uniqKey="Minami C" first="Christina A" last="Minami">Christina A. Minami</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, and Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, and Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Kantor, Olga" sort="Kantor, Olga" uniqKey="Kantor O" first="Olga" last="Kantor">Olga Kantor</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, and Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, and Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Weiss, Anna" sort="Weiss, Anna" uniqKey="Weiss A" first="Anna" last="Weiss">Anna Weiss</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, and Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, and Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Nakhlis, Faina" sort="Nakhlis, Faina" uniqKey="Nakhlis F" first="Faina" last="Nakhlis">Faina Nakhlis</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, and Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, and Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="King, Tari A" sort="King, Tari A" uniqKey="King T" first="Tari A" last="King">Tari A. King</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, and Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, and Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Mittendorf, Elizabeth A" sort="Mittendorf, Elizabeth A" uniqKey="Mittendorf E" first="Elizabeth A" last="Mittendorf">Elizabeth A. Mittendorf</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, and Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA. Electronic address: emittendorf@bwh.harvard.edu.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, and Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston</wicri:cityArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of the American College of Surgeons</title>
<idno type="eISSN">1879-1190</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent (MeSH)</term>
<term>Adult (MeSH)</term>
<term>Aged (MeSH)</term>
<term>Aged, 80 and over (MeSH)</term>
<term>Betacoronavirus (MeSH)</term>
<term>Biomarkers, Tumor (metabolism)</term>
<term>Breast Neoplasms (diagnosis)</term>
<term>Breast Neoplasms (epidemiology)</term>
<term>Breast Neoplasms (surgery)</term>
<term>Carcinoma, Ductal, Breast (diagnosis)</term>
<term>Carcinoma, Ductal, Breast (epidemiology)</term>
<term>Carcinoma, Ductal, Breast (surgery)</term>
<term>Comorbidity (MeSH)</term>
<term>Coronavirus Infections (epidemiology)</term>
<term>Female (MeSH)</term>
<term>Follow-Up Studies (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Mastectomy (methods)</term>
<term>Middle Aged (MeSH)</term>
<term>Neoplasm Staging (MeSH)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (epidemiology)</term>
<term>Prognosis (MeSH)</term>
<term>Receptors, Estrogen (metabolism)</term>
<term>Retrospective Studies (MeSH)</term>
<term>Risk Factors (MeSH)</term>
<term>Survival Rate (trends)</term>
<term>Time Factors (MeSH)</term>
<term>Time-to-Treatment (MeSH)</term>
<term>United States (epidemiology)</term>
<term>Young Adult (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent (MeSH)</term>
<term>Adulte (MeSH)</term>
<term>Adulte d'âge moyen (MeSH)</term>
<term>Betacoronavirus (MeSH)</term>
<term>Carcinome canalaire du sein (chirurgie)</term>
<term>Carcinome canalaire du sein (diagnostic)</term>
<term>Carcinome canalaire du sein (épidémiologie)</term>
<term>Comorbidité (MeSH)</term>
<term>Délai jusqu'au traitement (MeSH)</term>
<term>Facteurs de risque (MeSH)</term>
<term>Facteurs temps (MeSH)</term>
<term>Femelle (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Infections à coronavirus (épidémiologie)</term>
<term>Jeune adulte (MeSH)</term>
<term>Marqueurs biologiques tumoraux (métabolisme)</term>
<term>Mastectomie (méthodes)</term>
<term>Pandémies (MeSH)</term>
<term>Pneumopathie virale (épidémiologie)</term>
<term>Pronostic (MeSH)</term>
<term>Récepteurs des oestrogènes (métabolisme)</term>
<term>Stadification tumorale (MeSH)</term>
<term>Sujet âgé (MeSH)</term>
<term>Sujet âgé de 80 ans ou plus (MeSH)</term>
<term>Taux de survie (tendances)</term>
<term>Tumeurs du sein (chirurgie)</term>
<term>Tumeurs du sein (diagnostic)</term>
<term>Tumeurs du sein (épidémiologie)</term>
<term>États-Unis (épidémiologie)</term>
<term>Études de suivi (MeSH)</term>
<term>Études rétrospectives (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Biomarkers, Tumor</term>
<term>Receptors, Estrogen</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>United States</term>
</keywords>
<keywords scheme="MESH" qualifier="chirurgie" xml:lang="fr"><term>Carcinome canalaire du sein</term>
<term>Tumeurs du sein</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Breast Neoplasms</term>
<term>Carcinoma, Ductal, Breast</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Carcinome canalaire du sein</term>
<term>Tumeurs du sein</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Breast Neoplasms</term>
<term>Carcinoma, Ductal, Breast</term>
<term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Mastectomy</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Marqueurs biologiques tumoraux</term>
<term>Récepteurs des oestrogènes</term>
</keywords>
<keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Mastectomie</term>
</keywords>
<keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Breast Neoplasms</term>
<term>Carcinoma, Ductal, Breast</term>
</keywords>
<keywords scheme="MESH" qualifier="tendances" xml:lang="fr"><term>Taux de survie</term>
</keywords>
<keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Survival Rate</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Carcinome canalaire du sein</term>
<term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
<term>Tumeurs du sein</term>
<term>États-Unis</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Betacoronavirus</term>
<term>Comorbidity</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Middle Aged</term>
<term>Neoplasm Staging</term>
<term>Pandemics</term>
<term>Prognosis</term>
<term>Retrospective Studies</term>
<term>Risk Factors</term>
<term>Time Factors</term>
<term>Time-to-Treatment</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Betacoronavirus</term>
<term>Comorbidité</term>
<term>Délai jusqu'au traitement</term>
<term>Facteurs de risque</term>
<term>Facteurs temps</term>
<term>Femelle</term>
<term>Humains</term>
<term>Jeune adulte</term>
<term>Pandémies</term>
<term>Pronostic</term>
<term>Stadification tumorale</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Études de suivi</term>
<term>Études rétrospectives</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>États-Unis</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b>
</p>
<p>During the COVID-19 pandemic, surgical delays have been common for patients with ductal carcinoma in situ (DCIS) and early-stage estrogen receptor-positive (ER+) breast cancer, often in favor of neoadjuvant endocrine therapy (NET). To understand possible ramifications of these delays, we examined the association between time to operation and pathologic staging and overall survival (OS).</p>
</div>
<div type="abstract" xml:lang="en"><p><b>STUDY DESIGN</b>
</p>
<p>Patients with DCIS or ER+ cT1-2N0 breast cancer treated from 2010 through 2016 were identified in the National Cancer Database. Time to operation was recorded. Factors associated with pathologic upstaging were examined using logistic regression analyses. Cox proportional hazard models were used to analyze OS. Analyses were stratified by disease stage and initial treatment strategy.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>There were 378,839 patients identified. Among those undergoing primary surgical procedure, time to operation was within 120 days in > 98% in all groups. Among cT1-2N0 patients selected for NET, operations were performed within 120 days in 59.6% of cT1N0 and 30.9% of cT2N0 patients. Increased time to operation was associated with increased odds of pathologic upstaging in DCIS patients (ER+: 60 to 120 days: odds ratio 1.15; 95% CI, 1.08 to 1.22; more than 120 days: odds ratio 1.44; 95% CI, 1.24 to 1.68; ER-: 60 to 120 days: NS; more than 120 days: odds ratio 1.36; 95% CI, 1.01 to 1.82; 60 days or less: reference), but not in patients with invasive cancer, irrespective of initial treatment strategy. No difference in OS was seen by time to operation in DCIS or NET patients.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b>
</p>
<p>Increased time to operation was associated with a small increase in pathologic upstaging in DCIS patients, but did not impact OS. In patients with cT1-2N0 disease, NET use did not impact stage or OS, supporting the safety of delay strategies in ER+ breast cancer patients during the pandemic.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32771654</PMID>
<DateCompleted><Year>2020</Year>
<Month>09</Month>
<Day>29</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>09</Month>
<Day>29</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1190</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>231</Volume>
<Issue>4</Issue>
<PubDate><Year>2020</Year>
<Month>10</Month>
</PubDate>
</JournalIssue>
<Title>Journal of the American College of Surgeons</Title>
<ISOAbbreviation>J Am Coll Surg</ISOAbbreviation>
</Journal>
<ArticleTitle>Association Between Time to Operation and Pathologic Stage in Ductal Carcinoma in Situ and Early-Stage Hormone Receptor-Positive Breast Cancer.</ArticleTitle>
<Pagination><MedlinePgn>434-447.e2</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S1072-7515(20)30544-5</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jamcollsurg.2020.06.021</ELocationID>
<Abstract><AbstractText Label="BACKGROUND">During the COVID-19 pandemic, surgical delays have been common for patients with ductal carcinoma in situ (DCIS) and early-stage estrogen receptor-positive (ER+) breast cancer, often in favor of neoadjuvant endocrine therapy (NET). To understand possible ramifications of these delays, we examined the association between time to operation and pathologic staging and overall survival (OS).</AbstractText>
<AbstractText Label="STUDY DESIGN">Patients with DCIS or ER+ cT1-2N0 breast cancer treated from 2010 through 2016 were identified in the National Cancer Database. Time to operation was recorded. Factors associated with pathologic upstaging were examined using logistic regression analyses. Cox proportional hazard models were used to analyze OS. Analyses were stratified by disease stage and initial treatment strategy.</AbstractText>
<AbstractText Label="RESULTS">There were 378,839 patients identified. Among those undergoing primary surgical procedure, time to operation was within 120 days in > 98% in all groups. Among cT1-2N0 patients selected for NET, operations were performed within 120 days in 59.6% of cT1N0 and 30.9% of cT2N0 patients. Increased time to operation was associated with increased odds of pathologic upstaging in DCIS patients (ER+: 60 to 120 days: odds ratio 1.15; 95% CI, 1.08 to 1.22; more than 120 days: odds ratio 1.44; 95% CI, 1.24 to 1.68; ER-: 60 to 120 days: NS; more than 120 days: odds ratio 1.36; 95% CI, 1.01 to 1.82; 60 days or less: reference), but not in patients with invasive cancer, irrespective of initial treatment strategy. No difference in OS was seen by time to operation in DCIS or NET patients.</AbstractText>
<AbstractText Label="CONCLUSIONS">Increased time to operation was associated with a small increase in pathologic upstaging in DCIS patients, but did not impact OS. In patients with cT1-2N0 disease, NET use did not impact stage or OS, supporting the safety of delay strategies in ER+ breast cancer patients during the pandemic.</AbstractText>
<CopyrightInformation>Copyright © 2020 American College of Surgeons. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Minami</LastName>
<ForeName>Christina A</ForeName>
<Initials>CA</Initials>
<AffiliationInfo><Affiliation>Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, and Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kantor</LastName>
<ForeName>Olga</ForeName>
<Initials>O</Initials>
<AffiliationInfo><Affiliation>Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, and Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Weiss</LastName>
<ForeName>Anna</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, and Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Nakhlis</LastName>
<ForeName>Faina</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, and Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>King</LastName>
<ForeName>Tari A</ForeName>
<Initials>TA</Initials>
<AffiliationInfo><Affiliation>Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, and Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mittendorf</LastName>
<ForeName>Elizabeth A</ForeName>
<Initials>EA</Initials>
<AffiliationInfo><Affiliation>Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, and Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA. Electronic address: emittendorf@bwh.harvard.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016448">Multicenter Study</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>08</Month>
<Day>06</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>J Am Coll Surg</MedlineTA>
<NlmUniqueID>9431305</NlmUniqueID>
<ISSNLinking>1072-7515</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011960">Receptors, Estrogen</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName>
<SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName>
</SupplMeshList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018270" MajorTopicYN="N">Carcinoma, Ductal, Breast</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008408" MajorTopicYN="N">Mastectomy</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009367" MajorTopicYN="Y">Neoplasm Staging</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011960" MajorTopicYN="N">Receptors, Estrogen</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName>
<QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D061665" MajorTopicYN="N">Time-to-Treatment</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>05</Month>
<Day>01</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>06</Month>
<Day>17</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>06</Month>
<Day>17</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>8</Month>
<Day>11</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>9</Month>
<Day>30</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>8</Month>
<Day>11</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32771654</ArticleId>
<ArticleId IdType="pii">S1072-7515(20)30544-5</ArticleId>
<ArticleId IdType="doi">10.1016/j.jamcollsurg.2020.06.021</ArticleId>
<ArticleId IdType="pmc">PMC7409804</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidSeniorV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000735 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 000735 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= CovidSeniorV1 |flux= Main |étape= Curation |type= RBID |clé= pubmed:32771654 |texte= Association Between Time to Operation and Pathologic Stage in Ductal Carcinoma in Situ and Early-Stage Hormone Receptor-Positive Breast Cancer. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i -Sk "pubmed:32771654" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd \ | NlmPubMed2Wicri -a CovidSeniorV1
This area was generated with Dilib version V0.6.37. |